Search PubMed⌕ Search

Biomedical subjects

M Shiomi

Publications and source records attributed to M Shiomi.

100 records · Page 6Linked to original sources
PubMed1984

[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].

A new anticancer therapy using tegafur encapsulated in slow-releasing granules (SF-SP) was orally administered at a dose of 1000 mg/day to 38 patients with cancer of the digestive organs. Twenty-eight of these patients were evaluable for response using the criteria of Saito and Koyama's clinical evaluation. Six of 28 patients showed effective response (21.4%). An effective response was observed in of 15 patients with gastric cancer (26.7%). Side-effects from this therapy were encountered in 14 patients (36.8%). An effective response was therefore demonstrated in patients with cancer of the digestive organs.

Administration, Oral↗
PubMed1983

Effect of orally administered polysaccharide from kefir grain on delayed-type hypersensitivity and tumor growth in mice.

The effect of oral administration of a polysaccharide (KGF-C), isolated from the kefir grain, on delayed-type hypersensitivity (DTH) induced by picryl chloride and on the growth of solid tumor was examined in mice. KGF-C caused an increase in DTH response in intact mice and also tumor-bearing mice. The growth of tumor inoculated after the DTH test was markedly inhibited in the groups with high DTH response. A significant correlation between the DTH response and the antitumor activity was observed in intact mice.

Administration, Oral↗
PubMed1982

Antitumor activity in mice of orally administered polysaccharide from Kefir grain.

The antitumor activity of a water-soluble polysaccharide (KGF-C), isolated from the Kefir grain, was studied in the mice subcutaneously inoculated with Ehrlich carcinoma (EC) or Sarcoma 180 (S-180). The growth of EC and S-180 solid tumor was inhibited by 40-59% and 21-81%, respectively, by oral administration of KGF-C as compared with the unadministered mice. The tumor growth was similarly inhibited by intraperitoneal administration. The mechanism of the antitumor activity of KGF-C was considered to be host-mediated because of the lack of direct in vitro effect on tumor cells.

Animals↗
PubMedDate not supplied

Effects of high-dose troglitaz one on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits.

UNLABELLED: To clarify the dose-response effects of troglitazone on insulin sensitivity and beta-cell function, we examined the effects of high-dose troglitazone (100 mg/day per animal, administered as a food admixture) on glucose and insulin metabolism in hyperinsulinemic Watanabe heritable hyperlipidemic (WHHL) rabbits, and compared the results with our previous results with low-dose troglitazone (10 mg /day per animal). MATERIALS AND METHODS: Glucose and insulin metabolism were quantitatively characterized by a minimal model technique as reported previously. RESULTS: When troglitazone was administrated at a high dose for 6 months, it reduced hyperinsulinemia as reflected by a reduced basal (steady-state) insulin concentration lb and the insulin response to a glucose load, improved beta-cell function as reflected by decreased second-phase post-hepatic insulin delivery to glucose phi2, and reduced insulin resistance as reflected by increased insulin sensitivity to glucose disposal Si, without affecting glucose tolerance as reflected by an unchanged rate of glucose utilization Kg or insulin-independent glucose disposal Sg. The reductions in Ib and phi2 and the increases in Si in WHHL rabbits treated with a high dose of troglitazone were greater (p<0.05) than those observed in WHHL rabbits treated with a low dose of troglitazone, as assessed by a two-way repeated measures analysis of variance and the Wilcoxon-Mann-Whitney test. CONCLUSION: In WHHL rabbits, troglitazone dose-dependently reduced hyperinsulinemia, improved beta-cell function, and increased insulin sensitivity.

Animals↗
PubMedDate not supplied

Two cases of histopathologically advanced (stage IV) early gastric cancers.

We report two cases of early gastric cancer with distant metastases (stage IV). At our institute 1428 cases of primary gastric cancer were resected between 1980 and 1997; 536 were diagnosed as early gastric cancer based on the resected specimens (304 cases of mucosal cancer, Tis--TNM classification--and 232 of submucosal cancer, T1). 528 of these 536 cases were classified as histological stage I, six as stage II, none as stage III and two as stage IV. The incidence of stage IV early gastric cancer was 0.14% of all gastric cancers and 0.37% of the early gastric cancers. The two patients with stage IV early gastric cancer were women. Both tumors were defined as early cancer because they were confined to the submucosa. One was a type 0 IIc + III early cancer, histologically classifiable as a small, moderately differentiated adenocarcinoma (tub2 according to the Japanese Classification of Gastric Carcinoma, G2; TNM classification: ICD-O C16), size 10 x 8 mm; the other was a surface spreading type 0 IIc, classifiable as a signet-ring cell carcinoma (sig, G3), size 50 x 35 mm. Stage IV factors were N3 in the first and ovarian metastasis (Krukenberg tumor) in the second case.

Adenocarcinoma↗